Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,058 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Takeda Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Food Effect Study of Febuxostat XR in Healthy Participants

NCT02374164
View directory record Official record
Conditions
Gout
Interventions
Febuxostat XR
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 3 Interventional Results available

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

NCT00462709
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Biological
Lead sponsor
Shire
Industry
Eligibility
1 Year and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
48
States / cities
Hoover, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers

NCT01807000
View directory record Official record
Conditions
Healthy
Interventions
Radiolabeled Prucalopride Succinate
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 17, 2026, 3:50 AM EDT
Recruiting Phase 2 Interventional

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

NCT07224100
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Ponatinib, Prednisone, Rituximab, Vincristine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00251745
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
95
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 17, 2026, 3:50 AM EDT
Completed No phase listed Observational

A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

NCT05743465
View directory record Official record
Conditions
Leukemia
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 4 Interventional Results available

Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity

NCT01707667
View directory record Official record
Conditions
Chronic Constipation
Interventions
prucalopride, PEG 3350
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 1 Interventional Results available

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

NCT03131167
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions
SHP639 (n=60), Placebo Comparator (n=24)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 17, 2026, 3:50 AM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

NCT00532311
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and stable statin therapy, Stable statin therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease

NCT00864851
View directory record Official record
Conditions
Fabry Disease
Interventions
Replagal
Biological
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • Iowa City, Iowa • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

NCT01217957
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 1 Interventional Results available

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

NCT00500903
View directory record Official record
Conditions
Advanced Malignancies
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 17, 2026, 3:50 AM EDT
Completed No phase listed Observational

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

NCT03546894
View directory record Official record
Conditions
Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung
Interventions
Brigatinib, Alectinib, Ceritinib, Lorlatinib, Any FDA Approved ALK Inhibitors
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Maynard, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 17, 2026, 3:50 AM EDT
Available No phase listed Expanded access

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

NCT05795361
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Idursulfase-IT
Drug
Lead sponsor
Takeda
Industry
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Phoenix, Arizona • Oakland, California • Wilmington, Delaware + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

MPC-004 for the Treatment of an Acute Gout Flare

NCT00506883
View directory record Official record
Conditions
Gout
Interventions
High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose), Placebo Control
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
83
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 17, 2026, 3:50 AM EDT
Recruiting No phase listed Observational

Gaucher Disease Outcome Survey (GOS)

NCT03291223
View directory record Official record
Conditions
Gaucher Disease
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
1,257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2028
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 2 Interventional Results available

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01435759
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg, Antidepressant + Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
60
States / cities
Little Rock, Arkansas • Anaheim, California • Chino, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 17, 2026, 3:50 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)

NCT03559517
View directory record Official record
Conditions
Crohn's Disease
Interventions
Ontamalimab, Placebo
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lancaster, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 2 Interventional Results available

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome

NCT00671515
View directory record Official record
Conditions
Depressive Disorder, Major, Metabolic Syndrome X
Interventions
Pioglitazone
Drug
Lead sponsor
Joseph Calabrese, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 17, 2026, 3:50 AM EDT
Active, not recruiting Phase 2 Interventional

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

NCT06254950
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
TAK-279, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Murrieta, California • Clearwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 17, 2026, 3:50 AM EDT
Completed No phase listed Observational

Pediatric Teduglutide Registry

NCT04832087
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Teduglutide
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 4 Interventional Results available

Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia

NCT00492232
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon and zolpidem, Placebo and zolpidem
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Hot Springs, Arkansas • Anaheim, California • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2010 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

NCT00819468
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Teduglutide
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 17, 2026, 3:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

NCT02382640
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Febuxostat XR, Maalox Advance Regular Strength liquid
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 17, 2026, 3:50 AM EDT